

Associate, Boston

Mergers and Acquisitions



T: 617.573.4895  
F: 617.305.4895  
jennifer.kamocsay@skadden.com

#### Education

J.D., Northeastern University School of Law, 2010

B.A., University of California, Los Angeles, 1992

#### Bar Admissions

Massachusetts

Jennifer Kamocsay represents private and public companies on a wide range of corporate and securities law matters, including mergers and acquisitions, securities law compliance, corporate finance transactions, corporate governance, takeover preparedness and other general corporate matters. Ms. Kamocsay's significant representations include:

- Merrimack Pharmaceuticals, Inc. in its asset sale to Ipsen S.A. for up to \$1.025 billion;
- IneoQuest Technologies, Inc. in its acquisition by Telestream, LLC, a portfolio company of Genstar Capital;
- Anokion SA in its collaboration with Celgene Switzerland LLC and its grant to Celgene Switzerland of an option to acquire Anokion;
- Citrix Systems, Inc. in connection with the spin-off and subsequent merger of its "Go To" business with LogMeIn, Inc.;
- Annapurna Therapeutics SAS in its combination with Avalanche Biotechnologies, Inc.;
- Almirall, S.A. in its acquisition of ThermiGen, LLC, a privately held medical aesthetics technology company;
- Gilead Sciences, Inc. in its collaboration with, and \$425 million equity investment in, Galapagos NV;
- Strongbridge Biopharma plc in its redomiciliation from Sweden to Ireland by means of an exchange offer in connection with its U.S. initial public offering;
- Dendreon Corporation in its Chapter 11 filing and proposed restructuring of \$620 million of convertible notes and in its sale of Provenge and other assets to Valeant Pharmaceuticals International, Inc. for \$495 million;
- NPS Pharmaceuticals, Inc. in its \$5.2 billion acquisition by Shire plc;
- Covidien Group S.a.r.l. in its acquisition of an option to acquire privately held medical device company Foundry Innovation & Research 1, Limited;
- Savient Pharmaceuticals, Inc. in its Chapter 11 filing and sale of assets to Crealta Pharmaceuticals LLC for \$120 million;
- OfficeMax Incorporated in its \$1.2 billion merger of equals with Office Depot, Inc.;
- EMC Corporation in several matters, including:
  - its \$5.5 billion registered offering of senior notes;
  - the formation of Pivotal Software, Inc., its \$946 million joint venture with VMware, Inc.; and
  - its strategic worldwide partnership with Lenovo;
- Select Income REIT in its \$200 million initial public offering; and
- Sonesta Acquisition Corp. in its \$115 million acquisition of Sonesta International Hotels Corporation.